Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Mol Neurobiol ; 61(8): 5142-5160, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38172288

ABSTRACT

Alzheimer's disease (AD) is characterized by the accumulation of aggregated amyloid peptides in the brain parenchyma and within the walls of cerebral vessels. The hippocampus-a complex brain structure with a pivotal role in learning and memory-is implicated in this disease. However, there is limited data on vascular changes during AD pathological degeneration in this susceptible structure, which has distinctive vascular traits. Our aim was to evaluate vascular alterations in the hippocampus of AD patients and PDAPP-J20 mice-a model of AD-and to determine the impact of Aß40 and Aß42 on endothelial cell activation. We found a loss of physical astrocyte-endothelium interaction in the hippocampus of individuals with AD as compared to non-AD donors, along with reduced vascular density. Astrocyte-endothelial interactions and levels of the tight junction protein occludin were altered early in PDAPP-J20 mice, preceding any signs of morphological changes or disruption of the blood-brain barrier in these mice. At later stages, PDAPP-J20 mice exhibited decreased vascular density in the hippocampus and leakage of fluorescent tracers, indicating dysfunction of the vasculature and the BBB. In vitro studies showed that soluble Aß40 exposure in human brain microvascular endothelial cells (HBMEC) was sufficient to induce NFκB translocation to the nucleus, which may be linked with an observed reduction in occludin levels. The inhibition of the membrane receptor for advanced glycation end products (RAGE) prevented these changes in HBMEC. Additional results suggest that Aß42 indirectly affects the endothelium by inducing astrocytic factors. Furthermore, our results from human and mouse brain samples provide evidence for the crucial involvement of the hippocampal vasculature in Alzheimer's disease.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Astrocytes , Hippocampus , Alzheimer Disease/pathology , Alzheimer Disease/metabolism , Animals , Astrocytes/metabolism , Astrocytes/pathology , Humans , Hippocampus/pathology , Hippocampus/metabolism , Amyloid beta-Peptides/metabolism , Male , Aged , Mice, Transgenic , Female , Disease Models, Animal , Endothelial Cells/metabolism , Endothelial Cells/pathology , Aged, 80 and over , Blood-Brain Barrier/pathology , Blood-Brain Barrier/metabolism , Mice , Receptor for Advanced Glycation End Products/metabolism
2.
Opt Express ; 24(25): 28731-28738, 2016 Dec 12.
Article in English | MEDLINE | ID: mdl-27958516

ABSTRACT

We report an efficient energy-time entangled photon-pair source based on four-wave mixing in a CMOS-compatible silicon photonics ring resonator. Thanks to suitable optimization, the source shows a large spectral brightness of 400 pairs of entangled photons /s/MHz for 500 µW pump power, compatible with standard telecom dense wavelength division multiplexers. We demonstrate high-purity energy-time entanglement, i.e., free of photonic noise, with near perfect raw visibilities (> 98%) between various channel pairs in the telecom C-band. Such a compact source stands as a path towards more complex quantum photonic circuits dedicated to quantum communication systems.

3.
Article in English | MEDLINE | ID: mdl-27279754

ABSTRACT

OBJECTIVES: The aim of the current study is to collect scientific data on all branded hyaluronic acid (HA) products in Italy that are in use for intra-articular (IA) injection in osteoarthritis (OA) compared with that reported in the leaflet. METHODS: An extensive literature research was performed for all articles reporting data on the IA use of HA in OA. Selected studies were taken into consideration only if they are related to products based on HAs that are currently marketed in Italy with the specific joint indication for IA use in patients affected by OA. RESULTS: Sixty-two HA products are marketed in Italy: 30 products are indicated for the knee but only 8 were proved with some efficacy; 9 products were effective for the hip but only 6 had hip indication; 7 products proved to be effective for the shoulder but only 3 had the indication; 5 products proved effective for the ankle but only one had the indication; 6 products were effective for the temporomandibular joint but only 2 had the indication; only 2 proved effective for vertebral facet joints but only 1 had the indication; and 5 products proved effective for the carpometacarpal joint but only 2 had the indication. CONCLUSIONS: There are only a few products with some evidences, while the majority of products remain without proof. Clinicians and regulators should request postmarketing studies from pharmaceuticals to corroborate with that reported in the leaflet and to gather more data, allowing the clinicians to choose the adequate product for the patient.

4.
Article in English | MEDLINE | ID: mdl-27257398

ABSTRACT

BACKGROUND: The use of hyaluronic acid (HA) for intra-articular (IA) injection is widespread around the world for patients affected by osteoarthritis. AIM: The aim of this study is to identify scientific evidence from in vitro and in vivo studies supporting the use of IA HAs marketed in Italy. We also evaluated the accuracy of indications and contraindications reported in the leaflets of such HAs compared with the available scientific evidence. MATERIALS AND METHODS: An extensive literature search was performed to identify all in vitro and in vivo model studies reporting on the effects of various HAs marketed in Italy for IA use. Data reported in the leaflets of different HA-based products for IA use were extracted and analyzed alongside evidence from in vitro and in vivo model studies. RESULTS: Nine in vitro studies and 11 studies on animal models were examined. Comparing results with what is reported in the leaflets of HAs marketed in Italy, it was observed that many branded formulations are introduced in the market without any reporting of basic scientific evidence. Only 12.82% and 17.95% of branded products had been shown to be effective with scientific evidence from in vitro and in vivo studies, respectively. The rationale of use of these products is based on their nature, as if a class effect existed such that all HAs would yield similar effects. CONCLUSIONS: Data on HAs deriving from in vitro and in vivo studies are scarce and relate to only a small percentage of products marketed in Italy. Many indications and contraindications are arbitrarily reported in Italian HA leaflets without the support of scientific evidence. Larger and brand-specific studies are necessary and should be reported in the leaflets to guide clinicians in making an appropriate choice regarding HA-based IA therapy.

5.
Phys Rev Lett ; 107(19): 191803, 2011 Nov 04.
Article in English | MEDLINE | ID: mdl-22181598

ABSTRACT

We present a search for a new particle T' decaying to a top quark via T' → t + X, where X goes undetected. We use a data sample corresponding to 5.7 fb(-1) of integrated luminosity of p p collisions with sqrt[s] = 1.96 TeV, collected at Fermilab Tevatron by the CDF II detector. Our search for pair production of T' is focused on the hadronic decay channel, pp → T'T' → tt + XX → bqq b qq + XX. We interpret our results in terms of a model where T' is an exotic fourth generation quark and X is a dark matter particle. The data are consistent with standard model expectations. We set a limit on the generic production of T'T' → tt + XX, excluding the fourth generation exotic quarks T' at 95% confidence level up to m(T') = 400 GeV/c(2) for m(X) ≤ 70 GeV/c(2).

6.
G Ital Med Lav Ergon ; 32(4 Suppl): 180-1, 2010.
Article in Italian | MEDLINE | ID: mdl-21438254

ABSTRACT

The evaluative approach of occupational therapy, centred on the person, on an analysis of performance and an assessment of the work environment, can provide important information for planning interventions to increase safety at work. The reliability of work performance is influenced by many factors, some of which are not directly dependent on humans, such as those related to the environment, to materials, to spaces, to places and to the organization of work; others, however, are closely related to human behaviours. For this reason, for the purpose of ensuring prevention of all harmful events, the process of risk evaluation must also include an analysis of the role of human behaviour and functional capacity. In our daily clinical practice, we Occupational Therapists use work to promote the wellbeing and health of people by involving them in activities, with the knowledge that every occupation is perceived by an individual as something particularly personal and significant.


Subject(s)
Occupational Health , Occupational Therapy , Task Performance and Analysis , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...